JZYY(SH:600750)2017-10-20 16:00Financial Performance - Net profit attributable to shareholders rose by 25.61% to CNY 320,944,928.56 for the first nine months of the year[7]. - Operating revenue for the first nine months increased by 19.81% to CNY 1,307,645,844.40 compared to the same period last year[7]. - The company reported a diluted earnings per share of CNY 1.07, an increase of 25.88% compared to the previous year[7]. - Total operating revenue for Q3 2017 reached ¥429,980,386.21, a significant increase of 94.7% compared to ¥220,793,904.94 in Q3 2016[34]. - Operating profit for Q3 2017 was ¥132,900,563.27, up 90.9% from ¥69,678,776.42 in the same period last year[34]. - Net profit attributable to the parent company for Q3 2017 was ¥110,500,922.32, representing a 87.5% increase from ¥58,930,246.58 in Q3 2016[35]. - The total profit for Q3 2017 was ¥130,861,871.31, a rise of 88.8% compared to ¥69,351,047.43 in Q3 2016[35]. - The total comprehensive income for Q3 2017 was CNY 117,233,317.37, up from CNY 69,068,243.03 in Q3 2016, marking an increase of approximately 69.9%[39]. Asset and Liability Changes - Total assets increased by 4.72% to CNY 3,210,535,399.59 compared to the end of the previous year[7]. - The ending balance of notes receivable was RMB 711.28 million, an increase of RMB 261.88 million or 58.27% compared to the end of last year[19]. - The ending balance of accounts receivable was RMB 19.09 million, an increase of RMB 5.54 million or 40.84% compared to the end of last year[19]. - The ending balance of construction in progress was RMB 190.10 million, an increase of RMB 94.82 million or 99.51% compared to the end of last year[19]. - The ending balance of short-term borrowings was zero, a decrease of RMB 30 million or 100% compared to the end of last year[19]. - The company’s total liabilities decreased significantly, with a notable reduction in pre-receipts of RMB 83.13 million, a decrease of 37.01% compared to the end of last year[19]. - Total liabilities amounted to CNY 393,599,558.87, down from CNY 449,964,657.29, reflecting a decrease of around 12.5%[28]. - Current liabilities decreased to CNY 292,219,392.20 from CNY 425,593,187.87, a reduction of approximately 31.4%[28]. Cash Flow and Investment Activities - The net cash flow from operating activities decreased by 74.79% to CNY 146,676,888.64 compared to the same period last year[7]. - The cash flow from operating activities for the first nine months of 2017 was CNY 146,676,888.64, significantly lower than CNY 581,777,408.58 in the same period last year, a decrease of about 74.8%[42]. - The company reported a net cash outflow from investing activities of CNY -172,254,337.44 for the first nine months of 2017, compared to a net inflow of CNY 6,201,683.65 in the previous year[42]. - Total cash outflow from investing activities was $314.85 million, significantly higher than $140.18 million in the previous year, resulting in a net cash flow from investing activities of -$203.79 million[46]. - Cash paid for investments increased to $160 million from $90 million year-on-year, reflecting a significant rise in investment activities[46]. Regional Performance - Revenue from the East China region grew by 20.43% to CNY 325,645,899.38[15]. Cost and Expense Management - The gross profit margin for the pharmaceutical segment decreased by 2.38 percentage points, primarily due to rising raw material costs[13]. - The gross profit margin for non-prescription drugs decreased by 3.39 percentage points[13]. - The company’s financial expenses for the period were RMB -6.75 million, a decrease of RMB 7.60 million or 886.27% compared to the same period last year, due to reduced interest expenses from repaying bank loans[20]. - Total operating costs for Q3 2017 amounted to ¥297,294,538.71, an increase of 94.5% from ¥152,739,086.41 in Q3 2016[34]. - Sales expenses for Q3 2017 were ¥131,219,277.26, up 154.5% from ¥51,577,359.89 in Q3 2016[34].